12 Health Care Stocks Moving In Friday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Friday's after-market session, several healthcare stocks experienced significant movements. Forte Biosciences (FBRX) saw an 11.8% increase, while Telesis Bio (TBIO) rose by 10.81%. AcelRx Pharmaceuticals (ACRX), DermTech (DMTK), Renalytix (RNLX), and IN8bio (INAB) also gained. Conversely, Nautilus Biotechnology (NAUT), OpGen (OPGN), Bone Biologics (BBLG), ProSomnus (OSA), Kintara Therapeutics (KTRA), and Altamira Therapeutics (CYTO) declined. The movements were attributed to recent earnings reports and trading volumes.
November 17, 2023 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AcelRx Pharmaceuticals' stock moved upwards by 8.16% to $0.53, potentially reacting to market dynamics or recent company developments.
ACRX's stock price increase may be influenced by general market sentiment or undisclosed company-specific news, as no recent earnings report was mentioned.
CONFIDENCE 60
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
DermTech's stock increased by 7.33% to $1.61, reflecting possible investor confidence in the company's value.
DMTK's stock price rise could be attributed to positive investor sentiment or recent company achievements, as no specific catalyst was mentioned in the article.
CONFIDENCE 60
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Forte Biosciences' stock increased by 11.8% to $0.5 after its Q3 earnings report 4 days ago, with a significant surge in trading volume.
The positive movement in FBRX's stock price is likely due to the recent Q3 earnings report, which may have been better than expected, as indicated by the surge in after-market trading volume.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
IN8bio's shares increased by 6.0% to $0.96, possibly due to market trends or investor perception of the company's prospects.
INAB's stock appreciation might be driven by overall market movements or positive views on the company's future, as no specific news was highlighted.
CONFIDENCE 60
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Renalytix's stock rose 7.04% to $0.59 following their Q1 earnings report 3 days ago, indicating a favorable investor reaction.
The increase in RNLX's stock price is likely due to a positive response to the Q1 earnings report, as suggested by the recent rise.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Telesis Bio's shares rose 10.81% to $0.41, with trading volume significantly higher than average following their Q3 earnings report.
The increase in TBIO's stock price and the exceptionally high trading volume indicate a positive investor response to the Q3 earnings report.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Bone Biologics' stock decreased by 9.76% to $0.55, with Q3 earnings released 3 days ago potentially driving the downturn.
BBLG's stock price drop may be a direct response to the Q3 earnings report, which could have failed to meet investor expectations.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Altamira Therapeutics' stock fell 7.15% to $0.26, with a significant increase in trading volume indicating a strong market reaction.
CYTO's stock price decline, accompanied by a large trading volume, suggests a significant market reaction, possibly due to recent earnings or other news.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Kintara Therapeutics' shares declined by 7.63% to $0.34 following their Q1 earnings report, indicating a possible negative investor reaction.
The decrease in KTRA's stock price is likely due to investor disappointment with the Q1 earnings report, as suggested by the decline.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Nautilus Biotechnology's stock declined by 10.5% to $2.71, which could reflect investor concerns or a negative market reaction.
NAUT's stock price decrease may be due to negative investor sentiment or unfavorable market conditions, as no specific reason was provided.
CONFIDENCE 60
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
OpGen's stock decreased by 9.83% to $0.41 following their Q3 earnings report 3 days ago, suggesting a bearish investor response.
The decline in OPGN's stock price is likely a result of a negative reaction to the Q3 earnings report, as indicated by the recent drop.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
ProSomnus' stock declined by 8.03% to $0.46, possibly due to market sentiment or other external factors.
OSA's stock price fall could be influenced by general market trends or negative news not specified in the article.
CONFIDENCE 60
IMPORTANCE 50
RELEVANCE 50